| 摘要: |
| ［摘要］ 目的 探讨新辅助化疗TEC方案对晚期乳腺癌的治疗效果。方法 对28例Ⅲ、Ⅳ期乳腺癌患者行TEC新辅助化疗方案（多西紫杉醇75 mg/m2静脉滴入d1, 表阿霉素60 mg/m2静脉滴入d1, 环磷酰胺500 mg/m2静脉注射d1）, 21 d为1周期, 共2周期，并与未行任何术前治疗可手术的24例Ⅲa期患者作对比分析。结果 新辅助化疗组的总有效率为82.14%(23/28), 有64.28%(18/28)的患者分期降低。新辅助化疗组的平均无病生存期为49.6个月, 明显高于未行化疗组的40.2个月(P<0.05), 新辅助化疗组的50个月随访期无病生存率为32.14%, 对照组为29.16%，差异无统计学意义。结论 新辅助化疗能降低晚期乳腺癌患者的分期, 为手术创造最佳机会，减少或延缓肿瘤的复发、转移，并可延长晚期乳腺癌患者的无病生存期。 |
| 关键词: 乳腺肿瘤/药物疗法 紫杉烷类 表阿霉素 抗肿瘤联合化疗方案 |
| DOI：10.3969/j.issn.1674-3806.2009.11.16 |
| 分类号:R 737.9 |
| 基金项目: |
|
| A clinical study of the combination of docetaxel, epirubicin and cyclophosphamide (TEC) as neoadjuvant chemotherapy regimen in the treatment of advanced breast cancer |
|
SUN Cheng-hou, ZHOU Qian, WANG Qing
|
|
Department of General Surgery, the First People′s Hospital of Xuanwei, Yunnan 655400, China
|
| Abstract: |
| ［Abstract］ Objective To study the clinical effect of neoadjuvant chemotherapy(TEC) on advanced breast cancer. Methods The TEC neoadjuvant chemotherapy ［CTX 500 mg/m2(1 st day), docetaxel 75 mg/m2(1 st day), and epirubicin 60 mg/ m2 (1 st day) every 3 weeks ］ was carried out in 28 advanced breast cancer patients for 2 cycles before operation, and compared with 24 concurrent operable patients with advanced cancer, who did not receive any preoperative therapy. Results The overall response rate was 82.14%(23/28) in TEC neoadjuvant chemotherapy group. The stages of 18 of the 24 patients(64.28%) was downgraded. The disease free survival time of the patients was 49.6 months which was obviously longer than that of patients without neoadjuvant chemotherapy (40.2 months, P<0.05). The 50-month disease-free survival rate of the patients with neoadjuvant chemotherapy was 32.41% which was a little higher than that(29.16%) of the patients without the chemotherapy, but the two groups had no significant difference. Conclusion Neoadjuvant chemotherapy can downgrade the stage of patients with advanced breast cancer, provide an optimal time for operation, obviously prolong the disease-free survival time of the patients, and reduce or delay recurrence or metastasis. |
| Key words: Breast tumor Drug therapy Taxanes Epirubicin Antineoplastic combined chemotherapy protocols |
